Loading patent…
AssigneeChelsea Therapeutics, Inc.
InventorsMichael J. Roberts, Simon Pedder
Estimating the term…
The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).
A method of treating a condition selected from the group consisting of a mood disorder, a sleep disorder, and an attention deficit disorder, the method comprising administering a pharmaceutical composition comprising a therapeutically effective amount of droxidopa, or a pharmaceutically acceptable ester, amide, salt, solvate, or prodrug thereof, to a subject in need of treatment of the condition.
A pharmaceutical composition comprising:
A method of treating a patient suffering from a condition at least partially arising from reduced blood flow in the brain, the method comprising administering to the patient an amount of droxidopa that is therapeutically effective to increase brain blood flow.
Dependencies are inferred from the claim text.